ChemicalBook > CAS DataBase List > Eculizumab

Eculizumab

Product Name
Eculizumab
CAS No.
219685-50-4
Chemical Name
Eculizumab
Synonyms
H5G1.1;Alexion;Soliris;Eculizumab;ECULIZUMABUM;Unii-A3ulp0F556;H5G1.1Vhc H5G1.1vlc;Eculizumab USP/EP/BP;Eculizumab, stock solution;Eculizumab (anti-Complement C5)
CBNumber
CB02491712
Formula Weight
0
MOL File
Mol file
More
Less

Eculizumab Property

storage temp. 
Store at -20°C
form 
Liquid
color 
Colorless to light yellow
CAS DataBase Reference
219685-50-4
More
Less

Safety

Hazardous Substances Data
219685-50-4(Hazardous Substances Data)
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

American Custom Chemicals Corporation
Product number
API0007496
Product name
ECULIZUMAB
Purity
95.00%
Packaging
5MG
Price
$498.98
Updated
2021/12/16
Biosynth Carbosynth
Product number
BE165588
Product name
Eculizumab
Packaging
1mg
Price
$500
Updated
2021/12/16
Biosynth Carbosynth
Product number
BE165588
Product name
Eculizumab
Packaging
2mg
Price
$700
Updated
2021/12/16
Biosynth Carbosynth
Product number
BE165588
Product name
Eculizumab
Packaging
5mg
Price
$1000
Updated
2021/12/16
DC Chemicals
Product number
013343
Product name
Eculizumab
Packaging
002
Price
$1200
Updated
2021/12/16
More
Less

Eculizumab Chemical Properties,Usage,Production

Description

Eculizumab, a fully humanized anti-C5 monoclonal antibody, was introduced for treating patients with PNH to reduce hemolysis. It is the first therapy to be approved for this rare and life-threatening form of hemolytic anemia. PNH is a clonal hematopoietic stem-cell disorder that is characterized by the production of abnormal red blood cells (RBCs) with a deficiency of surface proteins that protect the cells against attack by the body’s complement system. Complement-mediated destruction of the susceptible RBCs results in intravascular hemolysis, the primary clinical manifestation in all PNH patients. Previously, patients with PNH have mainly been managed supportively, with red cell transfusions as required, and treatments such as folate and iron supplementation, anticoagulation for thrombotic disease, and the occasional use of steroids during hemolytic crises. Allogenic stem cell transplantation is currently the only curative option for PNH; however, it is associated with significant morbidity and mortality. Eculizumab therapy is aimed at preventing red cell lysis through blockade of complement activation process and the production of the membrane attack complex. Eculizumab specifically binds to the human complement protein C5 with high affinity (IC50 = 2 nM) and inhibits its cleavage to C5a and C5b, which is a key step in the pathway leading to the membrane attack complex C5b-C9.
Eculizumab has been granted orphan drug status from both the FDA and European regulatory agencies.The most serious adverse reaction associated with eculizumab therapy is meningococcal infections. Eculizumab is contraindicated in patients who are not vaccinated against Neisseria meningitidis or who have N. meningitidis infections. The most common adverse reactions with eculizumab include headache (44%), nasopharyngitis (23%), back pain (19%), and nausea (16%).

Originator

Alexion (US)

Uses

Treatment of autoimmune disease such as rheumatoid arthritis, membranous nephritis, lupus nephritis, dermatomyositis, and autoimmune hemolytic anemias.

brand name

Soliris

General Description

Eculizumab (Soliris) is a monoclonal antibodythat binds to the terminal complement protein C5 inRBCs. This blocks the cleavage of C5 and halts the processof complement-mediated cell destruction of the RBCs.Eculizumab has been shown to be effective in treating PNHand in March 2007 was approved by the FDA for treatingPNH.

Clinical Use

Recombinant monoclonal antibody:
Paroxysmal nocturnal haemoglobinuria (PNH)
Atypical haemolytic uraemic syndrome (aHUS)
Refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody-positive (MG)

Metabolism

Human antibodies undergo endocytotic digestion in the cells of the reticuloendothelial system. Eculizumab contains only naturally occurring amino acids and has no known active metabolites. Human antibodies are predominately catabolised by lysosomal enzymes to small peptides and amino acids.

Eculizumab Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Eculizumab Suppliers

Chembest Research Laboratories Limited
Tel
+86-21-20908456
Fax
021-58180499
Email
sales@BioChemBest.com
Country
China
ProdList
6005
Advantage
61
Wuhan Fortuna Chemical Co., Ltd
Tel
027-59207852 13308628970
Fax
QQ3130921841
Email
buy@fortunachem.com
Country
China
ProdList
2866
Advantage
58
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
meilunui@163.com
Country
China
ProdList
4727
Advantage
58
Beijing HuaMeiHuLiBiological Chemical
Tel
010-56205725
Fax
010-65763397
Email
waley188@sohu.com
Country
China
ProdList
12335
Advantage
58
Nanjing Sunlida Biological Technology Co., Ltd.
Tel
025-57798810
Fax
025-57019371
Email
sales@sunlidabio.com
Country
China
ProdList
3239
Advantage
55
Sichuan Wei Keqi Biological Technology Co., Ltd.
Tel
028-81700200 18116577057
Fax
028-81705658
Email
3003855609@qq.com
Country
China
ProdList
7887
Advantage
56
Taizhou KEDE Chemical Co., Ltd
Tel
0576-84613060 13093829633
Fax
0576-84613060
Email
sales@kedechemical.com
Country
China
ProdList
298
Advantage
60
Chizhou Kailong Import and Export Trade Co., Ltd.
Tel
Fax
-
Email
xg01_gj@163.com
Country
China
ProdList
9484
Advantage
50
Shanghai Lollane Biological Technology Co.,Ltd.
Tel
021-52996696,15000506266 15000506266
Fax
+86-21-52996696
Country
China
ProdList
4566
Advantage
55
Shanghai Hanjing Chemicals Co., Ltd.
Tel
021-54285032 13641685631
Fax
+86 (21) 5443 7651
Email
gerry.shu@hanjingchemicals.com
Country
China
ProdList
76
Advantage
55
Shanghai EFE Biological Technology Co., Ltd.
Tel
021-65675885 18964387627
Fax
021-65675885
Email
info@efebio.com
Country
China
ProdList
9806
Advantage
58
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Fax
QQ:2853530913
Email
2853530910@QQ.com
Country
China
ProdList
8012
Advantage
62
Beijing Solarbio Science & Tecnology Co., Ltd.
Tel
010-50973130 4009686088
Email
3193328036@qq.com
Country
China
ProdList
29785
Advantage
68
Hubei widely chemical technology Co., Ltd.
Tel
027-59402396 13419635609
Fax
027-83989310
Email
13419635609@163.com
Country
China
ProdList
1984
Advantage
55
Hefei Hirisun Pharmatech Co., Ltd.
Tel
+86-0551-62678551 +86-15056975894
Fax
0551-62678551
Email
sales@hirisunpharm.com
Country
China
ProdList
181
Advantage
55
Wellman Pharmaceutical Group Limited
Tel
027-83778875 15807197853
Fax
027-83991220
Email
15807197853@163.com
Country
China
ProdList
4027
Advantage
58
Taizhou Crene Biotechnology Co. Ltd.
Tel
+86-0576-88813233 +86-13396860566
Email
sales@pharm-intermediates.com
Country
China
ProdList
1991
Advantage
58
Tianjin Kaifu Pharmaceutical Technology Co., Ltd.
Tel
18081075745
Email
chemflowtech@sina.com
Country
China
ProdList
1886
Advantage
58
Hangzhou Huarong Pharm Co., Ltd.
Tel
571-86758373 +8613588754946
Fax
0086-571-81131109
Email
sales@huarongpharm.com
Country
CHINA
ProdList
3148
Advantage
58
Dideu Industries Group Limited
Tel
+86-29-89586680 +86-15129568250
Email
1026@dideu.com
Country
China
ProdList
22784
Advantage
58
Hefei Hirisun Pharmatech Co., Ltd
Tel
+8615056975894
Fax
86-0551-62678551
Email
shawn@hirisunpharm.com
Country
CHINA
ProdList
9911
Advantage
58
Baoji Guokang Healthchem co.,ltd
Tel
+8615604608665 15604608665
Email
dominicguo@gk-bio.com
Country
CHINA
ProdList
9414
Advantage
58
AFINE CHEMICALS LIMITED
Tel
+86-0571-85134551
Fax
008657185134895
Email
sales@afinechem.com
Country
China
ProdList
15352
Advantage
58
Career Henan Chemica Co
Tel
+86-0371-86658258 +8613203830695
Fax
0371-86658258
Email
laboratory@coreychem.com
Country
China
ProdList
30239
Advantage
58
DC Chemicals
Tel
021-58447131 13564518121
Email
sales@dcchemicals.com
Country
China
ProdList
9409
Advantage
58
Changzhou Chenhong Biotechnology Co., Ltd.
Tel
0519-85788828 13775037613
Email
sales@chemrenpharm.com
Country
China
ProdList
3600
Advantage
58
Wuhan Dingtong Pharmaceutical Co., Ltd
Tel
027-59207795 18327179646
Fax
027-59207795
Email
18327179646@163.com
Country
China
ProdList
1989
Advantage
58
Guangzhou Hongyuan Chemical Co.,Ltd
Tel
15817493340
Email
981810490@qq.com
Country
China
ProdList
1566
Advantage
58
Wuhan Wiseman Bioengineering Co.,Ltd
Tel
027-59506022 13419526507
Fax
027-59506022
Email
13419526507@163.com
Country
China
ProdList
2992
Advantage
58
Wuhan Chemstan Biotechnology Co., Ltd.
Tel
027-65317797 15926423062
Fax
QQ:422450190
Email
422450190@qq.com
Country
China
ProdList
10424
Advantage
58
Hubei Zhongshan Medical Technology Co., Ltd
Tel
027-61907345 13397111514
Fax
3443707954
Email
w13397111514@163.com
Country
China
ProdList
1009
Advantage
58
Shanghai Minkai Biological Technology Co., Ltd
Tel
021-021-52919136 17315815539
Email
2804155403@qq.com
Country
China
ProdList
168
Advantage
58
Jiangxi ravel Biotechnology Co.,Ltd
Tel
400-880-2824 18107960669
Fax
18140514863
Email
79046690@qq.com
Country
China
ProdList
1267
Advantage
58
Abmole Bioscience Inc.
Tel
021-50967598 02150967598
Email
sales@abmole.cn
Country
China
ProdList
4494
Advantage
58
Nantong Hi-Future Biotechnology Co., Ltd
Tel
18051384581
Email
sales@chemhifuture.com
Country
China
ProdList
2998
Advantage
58
SUZHOU MAYSIXTH TRADING CO.LTD
Tel
17715515539
Email
zhangxin@maysixth.cn
Country
China
ProdList
58
Advantage
58
Hubei Kele Fine Chemical Co., Ltd
Tel
027-59101668 19945030958
Fax
027-59101668
Email
2881924765@qq.com
Country
China
ProdList
7890
Advantage
58
Hubei wei shi reagent group ltd., company
Tel
027-59102966 18717199209
Fax
027-59379337
Email
2853877583@qq.com
Country
China
ProdList
3010
Advantage
58
Bide Pharmatech Ltd.
Tel
400-1647117 13681763483
Email
product02@bidepharm.com
Country
China
ProdList
62075
Advantage
58
Jiangxi ravel Biotechnology Co.,Ltd
Tel
400-880-2824 15608648206
Email
1987516016@qq.com
Country
China
ProdList
2816
Advantage
58
Jiangxi ravel Biotechnology Co.,Ltd
Tel
185-0276-2003 18502762003;
Email
435918333@qq.com
Country
China
ProdList
2312
Advantage
58
Wuhan Yingnuo Pharmaceutical Technology Co., Ltd.
Tel
+86-027-59232304 15387063101
Email
2881924050@qq.com
Country
China
ProdList
9956
Advantage
58
Hubei Weideli Chemical Reagent Co.,Ltd.
Tel
027-59222918 13385289472
Email
Z13385289472@163.com
Country
China
ProdList
4924
Advantage
58
TargetMol Chemicals Inc.
Tel
4008200310
Email
marketing@tsbiochem.com
Country
China
ProdList
24644
Advantage
58
Hubei wei shi reagent group ltd., company
Tel
027-59105166 13125137732
Email
2853863890@qq.com
Country
China
ProdList
3310
Advantage
58
Hubei Wanye Zhongcheng Chemical Reagent Co., Ltd.
Tel
18671296875 18671296875
Email
1205035102@qq.com
Country
China
ProdList
4302
Advantage
58
Hubei Enxing Biotechnology Co., Ltd
Tel
16621771607
Email
exbio_tech@163.com
Country
China
ProdList
8190
Advantage
58
Biolab Reagents
Tel
027-65279366 18108604862
Email
products@biolabreagent.com
Country
China
ProdList
9818
Advantage
58
Wuhan Jingkangen Biomedical Technology Co., Ltd
Tel
13720134139 13720134139
Email
orders@jknbiochem.com
Country
China
ProdList
5821
Advantage
58
Wuhan Acumen Bio-Technology Co.,ltd
Tel
027-027-16602739303 16602739303
Email
673003916@qq.com
Country
China
ProdList
2964
Advantage
58
More
Less

View Lastest Price from Eculizumab manufacturers

Career Henan Chemica Co
Product
Eculizumab 219685-50-4
Price
US $1.80/KG
Min. Order
1g
Purity
98%
Supply Ability
1KG/10KG/100KG
Release date
2020-11-02
Hangzhou Huarong Pharm Co., Ltd.
Product
Eculizumab 219685-50-4
Price
US $0.00-0.00/g
Min. Order
100mg
Purity
99%
Supply Ability
100KG
Release date
2021-09-15
Dideu Industries Group Limited
Product
Eculizumab 219685-50-4
Price
US $1.10/g
Min. Order
1g
Purity
99.9%
Supply Ability
100 Tons min
Release date
2021-08-17

219685-50-4, EculizumabRelated Search:


  • Alexion
  • Eculizumab
  • H5G1.1
  • H5G1.1Vhc H5G1.1vlc
  • Soliris
  • Unii-A3ulp0F556
  • ECULIZUMABUM
  • IMMunoglobulin,anti-(huMan coMpleMent C5 a-chain) (huMan-Mouse Monoclonal 5G1.1 heavy chain), disulfide withhuMan-Mouse Monoclonal 5G1.1 light chain, diMer (9CI)
  • Eculizumab, stock solution
  • ECULIZUMAB COMPLEMENT C5 219685-50-4
  • Eculizumab USP/EP/BP
  • Research Grade Eculizumab(DHB90002)
  • inhibit,C5a,C5b,haemolysis,membrane attack complex,humanized monoclonal antibody,Anti-Human C5, Humanized Antibody,Complement System,Eculizumab,complement C5,Inhibitor,MAC
  • Eculizumab (anti-Complement C5)
  • 219685-50-4